ATORVALIQ
is an HMG-CoA reductase inhibitor (statin) indicated:
•
To reduce the risk of:
o
Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD.
o
MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD.
o
Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure (CHF), and angina in adults with clinically evident CHD.
•
As an adjunct to diet to reduce low-density lipoprotein (LDL-C) in:
o
Adults with primary hyperlipidemia.
o
Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).
•
As an adjunct to other LDL-C lowering therapies to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia.
•
As an adjunct to diet for the treatment of adults with:
o
Primary dysbetalipoproteinemia.
o
Hypertriglyceridemia.
